# US 2004/0082025 A1 · Modified yeasts and uses thereof, in particular for producing steroid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082025 A1
- Document ID: US20040082025A1
- Status: Published application
- Kind: A1
- Application number: 10/343,993
- Filed: 2003-10-21
- Published: 2004-04-29
- Earliest claimed: 2000-08-08
- Assignees: Aventis Pharma S.A.
- Inventors: Bruno Dumas; Gilles Cauet; Tilman Achstetter; Eric Degryse
- Web page: https://patentgrep.com/patent/US20040082025A1

## CPC

- C12N 9/0087: {Steroid 21-monooxygenase (1.14.99.10)}
- A61P 5/00: Drugs for disorders of the endocrine system
- C12P 33/06: Hydroxylating
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20αHSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.

## Claims

### Claim 1

Method for modifying a steroid compound, comprising bringing this compound or a precursor thereof into contact with a yeast having a reduced 20αHSD activity, or a preparation derived from such a yeast.

### Claim 2

Method for producing steroidal derivatives from hydroxysteroid compounds using a yeast having a reduced 20αHSD type activity, or a preparation derived from such a yeast.

### Claim 3 (depends on 2)

Method according to claim 2, in which the hydroxysteroid is hydroxyprogesterone or its precursors.

### Claim 4

Method for converting 17α-hydroxyprogesterone using a yeast having a reduced 20αHSD type activity, or a preparation derived from such a yeast.

### Claim 5 (depends on 4)

Method according to claim 4, for converting 17α-hydroxyprogesterone to 11-deoxycortisol.

### Claim 6

Method according to any one of the preceding claims, characterized in that the yeast has one or more nonfunctional GCY1 and/or YPR1 genes.

### Claim 7

Method according to any one of the preceding claims, characterized in that the yeast is a Saccharomyces yeast.

### Claim 8

Method according to one of the preceding claims, characterized in that the nonfunctional gene(s) exhibit(s) a deletion and/or an insertion.

### Claim 9 (depends on 8)

Method according to claim 8, characterized in that the nonfunctional gene(s) is (are) disrupted.

### Claim 10

Yeast strain, characterized in that it possesses a genetic modification of the YPR1 and/or GCY1 gene(s).

### Claim 11 (depends on 10)

Yeast strain according to claim 10, characterized in that the gene(s) is (are) replaced, completely or in part, by the URA3 marker gene.

### Claim 12 (depends on 10, 11)

Yeast strain according to claim 10 or 11, characterized in that the genetic modification is an inactivating modification, preferably a gene disruption.

### Claim 13 (depends on 10, 11, 12)

Yeast strain according to one of claims 10 to 12, characterized in that it is a Saccharomyces cerevisiae yeast.

### Claim 14 (depends on 10, 11, 12, 13)

Yeast strain according to one of claims 10 to 13, comprising a nonfunctional GCY1 gene and YPR1 gene, which are preferably disrupted.

### Claim 15 (depends on 10, 11, 12, 13, 14)

Acellular preparation derived from a yeast according to any one of claims 10 to 14.

### Claim 16

Method of modifying the 20αHSD activity of a yeast, comprising modifying the activity of the GCY1 and/or YPR1 gene of the said yeast.

### Claim 17 (depends on 16)

Method according to claim 16, intended to reduce or inhibit the 20αHSD activity of a yeast, comprising the inactivation, preferably by disruption, of the GCY1 and/or YPR1 gene of the said yeast.

### Claim 18 (depends on 10, 11, 12, 13, 14)

Use of a yeast according to one of claims 10 to 14, for the preparation of steroidal compounds.

### Claim 19

Use of a yeast having a reduced 20αHSD activity, or a preparation derived from such a yeast, for the preparation, production, synthesis, modification and/or improvement of steroidal compounds in vitro or ex vivo.

### Claim 20

Use of a yeast having a reduced 20αHSD activity, or a preparation derived from such a yeast, for the conversion of 17α-hydroxyprogesterone to 11-deoxycortisol.

### Claim 21 (depends on 10, 11, 12, 13, 14, 19, 20)

Use of a yeast according to claim 19 or 20, in which the yeast is according to one of claims 10 to 14.
